Increased Antibody Affinity Confers Broad In Vitro Protection against Escape Mutants of Severe Acute Respiratory Syndrome Coronavirus by Mridula Rani et al.
Increased Antibody Affinity Confers Broad In Vitro Protection against
Escape Mutants of Severe Acute Respiratory Syndrome Coronavirus
Mridula Rani,a Meagan Bolles,f Eric F. Donaldson,e Thomas Van Blarcom,b Ralph Baric,e Brent Iverson,a,c and George Georgioua,b,d
Institute of Cellular and Molecular Biology,a Department of Chemical Engineering,b Department of Chemistry and Biochemistry,c and Department of Molecular Genetics
and Microbiology,d The University of Texas at Austin, Austin, Texas, USA; Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina, USAe; and Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAf
Even though the effect of antibody affinity on neutralization potency is well documented, surprisingly, its impact on neutraliza-
tion breadth and escape has not been systematically determined. Here, randommutagenesis and DNA shuffling of the single-
chain variable fragment of the neutralizing antibody 80R followed by bacterial display screening using anchored periplasmic
expression (APEx) were used to generate a number of higher-affinity variants of the severe acute respiratory syndrome coronavi-
rus (SARS-CoV)-neutralizing antibody 80R with equilibrium dissociation constants (KD) as low as 37 pM, a>270-fold improve-
ment relative to that of the parental 80R single-chain variable fragment (scFv). As expected, antigen affinity was shown to corre-
late directly with neutralization potency toward the icUrbani strain of SARS-CoV. Additionally, the highest-affinity antibody
fragment displayed 10-fold-increased broad neutralization in vitro and completely protected against several SARS-CoV strains
containing substitutions associated with antibody escape. Importantly, higher affinity also led to the suppression of viral escape
mutants in vitro. Escape from the highest-affinity variant required reduced selective pressure and multiple substitutions in the
binding epitope. Collectively, these results support the hypothesis that engineered antibodies with picomolar dissociation con-
stants for a neutralizing epitope can confer escape-resistant protection.
Coronavirus-mediated severe acute respiratory syndrome(SARS) emerged from zoonotic reservoirs and caused epi-
demic disease outbreaks in late 2002 and early 2003 that posed a
threat to public health worldwide. The disease is characterized by
a rapidly progressive atypical pneumonia, and the causative agent
was identified as a novel group 2b coronavirus (SARS-CoV) (16).
Though the disease is now largely contained, a few sporadic cases
were reported in late 2003 and 2004 that were caused by different
isolates of SARS-CoV (15).
SARS-CoV is an enveloped, single-stranded positive-sense
RNA virus that infects the host cell via the binding of the spike (S)
glycoprotein of the viral envelope to the ACE2 (angiotensin-con-
verting enzyme 2) receptor of the host cell (3, 13). The receptor-
binding domain (RBD), a 193-amino-acid fragment located in the
S1 region of the S protein, is responsible for the initial binding
event (3). Sequence analyses of different SARS-CoV isolates have
revealed that the RBD is subject to strong selective pressure by
antibody immune responses in the host. Amino acid substitutions
within the RBD have played a major role in the ability of SARS-
CoVs to overcome the species barrier, initially allowing animal-
to-human transmission and subsequent adaptation to transmis-
sion among humans (39).
The high immunogenicity of the S protein as well as its crucial
role in the recognition of the host cell receptor and the initiation of
infection has made it an important target for both vaccine and
therapeutic development (3). Several monoclonal antibodies
(MAbs) to the S protein have been developed and shown to pro-
tect against SARS-CoV infection in vitro (18, 32). Additionally, a
variety of neutralizing antibodies (7, 20, 27, 44) have been shown
to confer protection in a mouse model. The best characterized of
these neutralizing antibodies, 80R, was isolated from a large naïve
human single-chain variable fragment (scFv) library using phage
display. 80R binds the S protein with a reported equilibrium dis-
sociation constant (KD) equal to 32 nM while recognizing a con-
formational epitope that overlaps the RBD in the S1 domain (28).
However, antibody-mediated selective pressure in vitro is known
to result in antigenic drift within the RBD, leading to the accumu-
lation of mutations that abolish neutralization by 80R (26).
Various strategies have been explored for developing broadly
neutralizing antibodies that can both protect against heterovari-
ant SARS-CoV strains present in the natural reservoirs and hinder
the generation of escapemutantswhen the virus is challengedwith
the neutralizing antibody. Rockx et al. and ter Meulen et al.
achieved broader neutralization against SARS-CoV escape mu-
tants using a combination of twomonoclonal antibodies that rec-
ognize nonoverlapping neutralizing epitopes on the S protein (20,
29). Rockx et al. were successful in isolating four broadly neutral-
izing antibodies from human memory B cells that neutralized
both zoonotic and human strains, and a cocktail of these antibod-
ies was proposed as a means for providing better protection
against infection (21). However, the development of a therapeutic
strategy comprising two or more recombinant antibodies raises
serious practical concerns. As an alternative, Sui and coworkers
engineered variants of the 80R scFv by structure-guided random-
ization of key residues in the V light chain. The resulting library
was screened by phage display toward the S protein RBD contain-
ing the dominant mutations found in escape variants (D480A or
D480G) fromhuman SARS-CoV isolates (26). Two antibody vari-
ants, fm6 and fm39,were shown to be broadly neutralizing in an in
vitro neutralization assay with pseudotyped virus containing the
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Tor2 or GD03 strain RBD or the D480A or D480G mutation.
These broadly neutralizing antibodies exhibited 10-fold-lower af-
finity than 80R for the Tor2 strain RBD, but unlike 80R, they also
bound RBD (D480A) and RBD (D480G)with nanomolar affinity.
The results of Sui et al. (26) revealed that in vitro selections can be
used to engineer broadly neutralizing antibodies; however, they
are predicated upon knowledge of the relevant escape mutations
and the availability of the respective protein variants required for
panning experiments.
It is well established that the potency of neutralizing antibodies
for either viruses or bacterial toxins depends on affinity (17, 35,
36). Surprisingly, engineering antibodies with increased affinity
has not been investigated as a strategy for conferring broader pro-
tection as a means to hinder escape. A higher antigen affinity re-
sults fromahigherGbinding.While antibody-antigen interactions
are often dominated by interactions with a binding “hot spot” on
the antigen, a high Gbinding can also arise from additional inter-
actions between the epitope and the paratope (14). Accordingly,
we hypothesized that increasing the affinity of 80R for the RBD
can elicit broader neutralization. Variants of the 80R scFv anti-
body fragment exhibiting up to 280-fold-higher affinity for the
RBD were generated by randommutagenesis and screening using
Escherichia coli display by anchored periplasmic expression
(APEx) (9). As expected, in vitro neutralization potency against
the icUrbani strain correlated directly with affinity. Importantly,
neutralization of viruses containing the RBD D480A or D480Y
mutation that evaded neutralization by 80R (28) also correlated
with affinity. Only reduced selective pressure with lower concen-
trations of the high-affinity antibody led to the evolution of SARS-
CoV escape mutants, which contained, in addition to D480Y or
D480A, secondary amino acid substitutions within the 80R
epitope.
MATERIALS AND METHODS
Bacterial strains and plasmids. Escherichia coli Jude1 (DH10B F::Tn10)
cells (8) were used for all the cloning and protein expression experiments
reported here. Plasmid pAPEx1 was used for N-terminal APEx display of
scFv and the construction of scFv libraries (9). pMopac16 contains a pelB
leader followed by SfiI sites used for cloning the scFv gene, a human kappa
light-chain constant domain for single-chain-antibody-fragment (scAb)
expression, a C-terminal 6-histidine tag for purification, and the Skp
chaperone to aid soluble-protein expression in the periplasmic space (10).
Viruses and cells. Recombinant viruses icUrbani (AY278741),
icGD03-MA, and icHC/SZ/61/03 were propagated in Vero E6 cells (22,
24, 38). Vero E6 was maintained in minimal essential medium (MEM)
(Invitrogen, Carlsbad, CA) supplemented with 10% Fetal Clone II (Hy-
Clone, South Logan, UT) and gentamicin and kanamycin (UNC Tissue
Culture Facility). Growth curves were performed in Vero E6 with the
different wild-type or mutant recombinant-derived escape mutant vi-
ruses at a multiplicity of infection (MOI) of 0.1 for 1 h and overlaid with
medium. Virus samples were collected at various time points postinfec-
tion and stored at 70°C until viral titers were determined by plaque
assay.
Virus titers were determined as PFU by plating 6-well plates with 5
105 Vero E6 cells per well and inoculating cultures with 200 l from the
10-fold serial dilutions. Cells were incubated with the virus for 1 h at 37°C
and overlaid with 3 ml of 0.8% agarose in complete medium. Plates were
incubated for 2 days at 37°C, and plaques were visualized by staining with
neutral red for 3 to 6 h. Virus concentration was calculated as PFU/ml. All
virus work was performed in a class II biological safety cabinet in a certi-
fied biosafety level 3 laboratory containing redundant exhaust fans; work-
ers wore Tyvek suits and powered air-purifying respirators.
Construction of an scFv library. The 80R single-chain antibody gene
(27) was constructed by overlap extension PCR (25). The heavy- and
light-chain variable regions of the antibody were amplified by PCR, and a
(Gly4Ser)4 linker was introduced by overlap extension PCR. The ampli-
fied 80R scFv PCR product was digested with SfiI and cloned into the
SfiI-digested pAPEx1 vector (9) for bacterial display. The 80R scFv gene
was subjected to randommutagenesis by error-prone PCRusing standard
protocols (6). A library of 1.6 108 independent transformants was ob-
tained. Sequencing of 10 random clones revealed a nucleotide substitu-
tion rate of 1.3%.
Cloning, expression, and purification of receptor-binding domain.
A gene encoding the S protein of the SARS-CoV Urbani strain
(AY278741) was generously provided by S. Makino (UTMB-Galveston)
and used to amplify the receptor-binding domain (RBD), consisting of
amino acids 318 to 518. The RBD was cloned into pFastbac vector (Invit-
rogen) with the N-terminal honeybee melittin signal sequence (30) for
secretion in insect cells, a C-terminal FLAG tag for screening, and an
N-terminal 6-His tag for purification. Bacmid DNA was prepared and
transfected into SF9 cells by using a Bac-Bac system (Invitrogen) accord-
ing to the manufacturer’s instructions to generate and amplify baculovi-
rus particles, and the titers were determined by following the Bac-Bac
protocol. High Five cells (Invitrogen) were cultured in insect Xpress me-
dium (Cambrex, Walkersville, MD) supplemented with 10% fetal bovine
serum (Sigma) and penicillin and streptomycin (Sigma) at 27°C as a
monolayer. To produce the RBD, insect cells were seeded at a density of
106/ml in 250 ml of medium and infected at a multiplicity of infection of
5 with recombinant RBD baculovirus. Media were harvested after 90 h,
and the culture supernatant was dialyzed against 1 IMAC (immobilized
metal affinity chromatography) buffer (10mMTris-HCl, 0.5MNaCl [pH
8.0]) at 4°C. Following dialysis, the culture supernatant containing the
RBD was incubated with 1 ml of nickel-nitrilotriacetic acid (Ni-NTA)
agarose (Qiagen, Hilden, Germany) for 2 h at 4°C. The mixture was then
loaded onto a 5-ml column and washed with 10 column volumes of 1
IMAC buffer. Protein was eluted with 3 column volumes of 1 IMAC
buffer with 300mM imidazole. The protein eluate was further purified on
a Superdex-200 (GE Healthcare) size exclusion column via fast protein
liquid chromatography (FPLC). Protein samples were analyzed for purity
on a 4 to 20% polyacrylamide gel (NuSep, Lawrenceville, GA) and stained
with Coomassie blue.
Screening and selection of high-affinity scFv variants by APEx. E.
coli strain Jude1 cells transformedwith the 80R scFv library in the pAPEx1
vector were used to inoculate shake flasks containing 20 ml of Terrific
broth (TB) medium (Difco, Sparks, MD) supplemented with chloram-
phenicol (Cm) at 35g/ml to an optical density at 600 nm (OD600) of 0.1.
Cells were grown at 37°C with shaking until the OD600 reached 0.5, at
which point cultures were transferred to a 25°C shaker for 30min. Protein
synthesis was induced with isopropyl--D-thiogalactopyranoside (IPTG)
to a final concentration of 1 mM, and incubation was continued for 3 h at
25°C with shaking. Two to three ml of cells equivalent to an OD600 of 10
were collected by centrifugation and resuspended in 350 l of ice-cold
Tris-sucrose (0.75M sucrose and 0.1M Tris-HCl [pH 8.0]) solution with
30l of 40g/ml lysozyme. An additional 700l of ice-cold 1mMEDTA
was added dropwise, and the mixture was incubated at 4°C on a rotary
shaker for 15 min. A 50-l portion of 0.5 M MgCl2 was then added, and
the mixture was incubated for another 10 min at 4°C on a rotary shaker.
Cells were then gently pelleted, resuspended in 1ml 1 PBS with purified
RBD (100 nM for the first round), and incubated for 40 min at room
temperature on a rotary shaker. Subsequently, the cells were pelleted again
and resuspended with 1 ml 1 PBS with 200 nM phycoerythrin (PE)-
conjugated anti-FLAG (Phycolink; Prozyme, San Leandro, CA) at room
temperature for 40 min. After labeling, the cells were pelleted and resus-
pended in 1 ml 1 PBS and analyzed on a FACS Aria (BD Biosciences)
flow cytometer using a 488-nm laser for excitation. The spheroplasts were
gated based on forward-scatter and side-scatter parameters. Five percent
of the most fluorescent cells were collected, and the sort population was
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re-sorted immediately. scFv genes in the re-sort solution were amplified
by PCR, cloned into the pAPEx1 vector, transformed into cells, and plated
on agar plates. The resulting clones were then subjected to an additional
three rounds of sorting as described above, except that decreasing concen-
trations of the RBD were used to increase the stringency of sorting as
follows: 100 nM in the first round, 50 nM in the second, 25 nM in the
third, and 20 nM in the final round.
After the fourth round of sorting via FACS, geneswere rescued by PCR
and cloned into pMopac16 (11) for soluble expression. For high-through-
put off-rate screening based on dissociation rate constants, colonies were
inoculated into a 96-well seed plate containing 200 l of TB with 2%
glucose and 200g/ml ampicillin per well. After overnight growth at 37°C
with shaking, 20 l of the culture from each well was used to inoculate
fresh 96-well plates with the same growth medium. The seed plate was
stored with 15% glycerol at20°C for future use. After overnight growth
at 37°C with shaking, cultures were pelleted by centrifugation at 4,500
rpm for 10 min. The medium was discarded; the cell pellets were resus-
pended in 200 l of expression medium (TB with 200 g/ml ampicillin
and 1 mM IPTG) and then incubated at 25°C for 3 h. The cells were
pelleted again by centrifugation at 4,500 rpm for 10 min, resuspended in
200 l of lysis buffer (20% BugBuster HT-Novagen in HBS-EP buffer),
and incubated with shaking at room temperature for 2 h. The lysates were
centrifuged to precipitate the insoluble fraction, and the lysate superna-
tant was transferred to a 96-well multiscreen HTS filter plate (Millipore,
Billerica, MA), set on a collection plate, and centrifuged for 10 min, and
clarified filtrate was collected in a 96-well collection plate. The clarified
filtrate was used for koff determination by surface plasmon resonance
(SPR) analysis using a BIAcore 3000 instrument (GEHealthcare, Uppsala,
Sweden) as follows: purified RBD was first covalently immobilized in 10
mM sodium acetate (pH 5.9) on a CM5 sensor chip (carboxymethylated
dextran matrix; GE Healthcare, Uppsala, Sweden) by using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide–N-hydroxysuccinimide chemistry
to the level of 300 response units (RUs). Bovine serum albumin (BSA)was
similarly coupled to the chip as an in-line subtraction standard. Kinetic
analysis was performed in HBS-EP buffer (GE Healthcare, Uppsala, Swe-
den) at a flow rate of 25 l/min at 25°C. Samples were injected over the
immobilized RBD for 2 min followed by a 5-min dissociation phase. The
surface was regenerated by injection of 10l of 4 MMgCl2 at a 50l/min
flow rate. Dissociation kinetics were calculated using BIAevaluation soft-
ware, and clones with the lowest off rates compared to that of 80R were
selected for further analysis.
Shuffling and randommutagenesis of isolated clones for additional
screening. The four highest-affinity scFv genes isolated from the off-rate
analysis described above, along with the 80R scFv gene, were chosen for
DNA shuffling. The four isolated genes were first amplified individually
by PCR, and the DNA products were pooled with a 4-fold molar excess of
80R scFv and then digested with 0.125 U of DNase I (Roche, Germany)
per 3 g of DNA at room temperature for 30 min. The reaction was
stopped by heat inactivation at 80°C for 10 min, and DNase I digest frag-
ments of 50 to 100 bp were gel purified using a QIAEX II (Qiagen) gel
extraction kit. The DNA fragments were reassembled by PCR for a few
rounds without primers; then full-length DNAwas amplified using exter-
nally flanking primers encoding SfiI sites. DNA was separated by agarose
gel electrophoresis, and a band750 bp in lengthwas excised, gel purified
using the Qiagen gel extraction kit (Qiagen), digested with SfiI, and then
ligated to SfiI-digested pAPEx1 vector. Following electroporation, 5.4 
107 transformants were obtained, and DNA sequencing of 10 clones se-
lected at random revealed the presence of recombination events as ex-
pected. PCR product after the assembly was also used as a template for
error-prone PCR as described above, and the DNA product from that
reaction was cloned into pAPEx1 vector to generate a library of 1.5 107
transformants with a nucleotide substitution rate of 0.5%.
The shuffled library and the error-prone library were pooled and sub-
jected to three rounds of FACS screening as described above. The concen-
tration of the RBD used for labeling was reduced in successive rounds as
follows: 20 nM for the first round, 10 nM for the second round, and 5 nM
for the final round. After the final round of sorting, scFv genes were PCR
amplified and subcloned into pMopac16. Subsequently, 96 colonies were
inoculated for high-throughput screening, cell lysates were prepared, and
dissociation rate constants were measured using SPR as described above.
Expression and purification of single-chain antibody fragments
(scAbs). Antibody fragments were expressed as scAbs by inserting the
scFv genes into pMopac16 vector, a pAK400 derivative in which the scFv
is fused in frame to a C-terminal human kappa light-chain constant do-
main.
Antibody fragments were expressed in E. coli Jude1 (DH10BF::Tn10)
(11). Individual colonies were inoculated into 50ml TBmediumwith 200
g/ml ampicillin and 2% glucose and were grown overnight at 37°C.
Overnight cultures were used to inoculate 500ml of TBmediumwith 200
g/ml ampicillin, and the cells were grown at 37°C for 3 h. Cultures were
transferred to 25°C for 30min, and protein expressionwas inducedwith 1
mM IPTG. After 4 h of incubation at 25°C, cells were collected by centrif-
ugation, and protein was purified from the osmotic shock fraction (11).
Briefly, cells were resuspended in 12 ml of ice-cold Tris-sucrose solution
(0.75 M sucrose, 100 mM Tris [pH 8]) with the addition of 1 ml of 30
g/ml lysozyme in Tris-sucrose buffer. Cells were gentlymixed for 10min
at 4°C, and 24ml of 1 mMEDTAwas added dropwise and allowed tomix
for an additional 20 min at 4°C. A 1.7-ml portion of 0.5 M MgCl2 was
added, and the mixture was incubated further for 10 min. The samples
were centrifuged at 12,000 rpm for 15 min, and the resulting supernatant
was dialyzed against 1 IMAC buffer (10 mMTris-HCl, 0.5 MNaCl [pH
8.0]). ScAbs were purified from the supernatant by IMAC using Ni-NTA
agarose according to the manufacturer’s protocol (Qiagen, Hilden, Ger-
many), followed by size exclusion FPLCon Superdex 200 (GEHealthcare)
as described above. The purity of isolated scAb was verified by gel electro-
phoresis on a 4 to 20%SDS-PAGE gel (NuSep, Lawrenceville, GA) stained
with Coomassie blue.
To remove the endotoxin from the purified scAbs for in vitro neutral-
ization assays, the purified protein samples were passed three times
through Detoxi-gel endotoxin removal columns (Pierce, Rockford, IL)
according to the manufacturer’s instructions. The endotoxin levels in the
samples were measured by the limulus amebocyte lysate (LAL) assay (As-
sociates of Cape Cod, East Falmouth, MA) as described by the manufac-
turer.
BIAcore analysis for affinity measurement. The purified RBD was
immobilized on aCM5 chip as described above, and BSA was used as
in-line subtraction. Kinetic analysis was performed in HBS-EP buffer at a
flow rate of 50l/min at 25°C. The affinity of the FPLC-purified scAbswas
analyzed by injecting the samples over the chip for 1 min for the associa-
tion phase followed by 10 min dissociation. Five different concentrations
of antibodies from 9 nM to 36 nM were analyzed in duplicate, along with
a blank as a reference. The surface regenerationwas performedwith a 12-s
injection of 4 MMgCl2. Binding kinetics were calculated using BIA eval-
uation software (GE Healthcare, Uppsala, Sweden). Calculated fits were
based on the Langmuir 1:1 model, with 2 values below 1.
Isolation of escape mutants under neutralizing antibody selective
pressure. icUrbani (1 106 PFU) was incubated with 20 g of a neutral-
izing scAb (RSK, SK4, or 80R) in a 200-l volume for 30 min and then
inoculated onto VeroE6 cells in the presence of the respective scAb anti-
body fragment at a concentration of 20 g/ml. The development of cyto-
pathic effect (CPE) was monitored over 72 h, and progeny viruses were
harvested. Antibody treatment was repeated two additional times, and
more rapid CPE was noted with each passage. The viruses from passage 4
were plaque purified in the presence of antibody; neutralization-resistant
viruses were stored at80°C, and titers were determined on VeroE6 cells
as described above. The S glycoprotein genes from four individual plaques
for each experimentwere sequenced, and the neutralization titers between
wild type and antibody-resistant viruses were determined as described
below.
In the experiment described above, the SK4 scAb resulted in the ex-
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tinction of parent viruses on three separate occasions. To increase the
probability of escape mutant evolution, we incubated 1  106 PFU of
icUrbani with decreasing concentrations of SK4 ScAb antibody fragment
(15, 10, 5, and 1g) for 30 min and then infected cultures in the presence
of 5 g/ml SK4 antibody. Depending on treatment conditions, cytopa-
thology eitherwas evidentwithin 48 h (5- and 1-g doses) orwasminimal
after 4 days (15 and 10 g). Low-dose-SK4-treated progeny viruses (1-
and 5-g doses) were treated with 5 g of SK4 for two passages and then
selected with two additional treatments of 10- and 15-g doses each,
resulting in highly antibody-resistant viruses that produced extensiveCPE
in cultureswithin 24 to 36 h.High-dose-treated stockswere passaged once
in the absence of antibody (pass 2) to restore virus titers and then rese-
lected twice in the presence of 5 g antibody. Two final treatments of 10
and 15 g of SK4 antibody resulted in highly resistant populations that
rapidly produced CPE in culture. Two to four plaques were isolated from
each treatment regimen (9 plaques total) in the presence of 20 g SK4
antibody, and the S glycoprotein gene was sequenced.
Plaque reduction neutralization test (PRNT). Each scAb in the panel
(80R, RSK, RS2, and SK4) was serially diluted 1:2 in PBS starting at 30
g/ml. Wild-type icUrbani, icGD03-MA, and icHC/SZ/61/03 were di-
luted, and approximately 100 PFU of each was added to the scAb dilution
series for 30 min at 37°C. The percentage neutralization was calculated as
[100  (number of plaques with antibody/number of plaques without
antibody)]  100. For 50% plaque reduction neutralization titers
(PRNT50s) of single-substitution variants, the viruses were diluted to 100
PFU and added to 2-fold serial dilutions of SK4 starting at 5 g/ml. The
single-substitution variants are escape mutants developed against mono-
clonal antibodies, as previously described (L443R and T332I [21] and
D480G [26]) or as described above (Y436H, Y442S, and N479I).
RESULTS
Generation of high-affinity variants of the 80R scFv antibody.
The RBD fused to a C-terminal FLAG peptide epitope (RBD-
FLAG) was produced in High Five insect cells, with a yield of
approximately 1.2 mg/liter. RBD-FLAG was purified to 	95%
homogeneity and was shown to bind to the 80R scAb (an scFv
fragment fused to a humanC chain for improved expression and
stability) with a dissociation constant in the nanomolar range,
consistent with earlier reports (27).
The 80R scFv library was expressed as a fusion to the signal
peptide and the first 6 amino acids of NlpA using the pAPEx1
vector. The short NlpA fusion anchors the scFv on the outer side
of the E. coli inner membrane (9). Following spheroplast forma-
tion, a limiting amount of labeled antigen (RBD-FLAG) was
added, followed by the addition of anti-FLAG PE; then screening
by FACS led to enrichment in higher-affinity variants. Around 5%
of the spheroplasts with the highest fluorescence were collected
and re-sorted. The scFv genes from the sorted cells were rescued
by PCR amplification and cloned back into pAPEx1. After three
additional rounds of sorting with decreasing concentrations of
RBD-FLAG from 100 nM to 20 nM (Fig. 1A), scFv genes were
rescued by PCR and expressed as soluble scAb antibody fragments
for biochemical analysis.
A total of 88 randomly picked colonies from round 4, as well as
8 colonies of cells expressing 80R scAb as controls, were grown in
a 96-well plate. Following chemical lysis, the koff rate constants of
the scAb proteins in the lysates were rank ordered by surface plas-
mon resonance (SPR) analysis. Four scAb antibody fragments dis-
playing the lowest antigen dissociation rates were expressed and
purified to near homogeneity by IMAC followed by gel filtration
FPLC. SPR analysis revealed that all the isolated scAbs exhibit
significantly lower KD values for RBD binding than the 80R anti-
body fragment and that the improvements in KD values arose
primarily because of lower koff values (9). The KD values of the
scAb variants ranged from 0.86 nM to 0.05 nM, with the highest-
affinity clone, RS2, exhibiting a koff of 1.34 10
4 s1 (Table 1).
This represents a 	200-fold improvement in affinity relative to
80R (KD
 10.5 nM).
Sequence analysis of the isolated clones revealed a variety of
mutations distributed over the entire length of the scFv gene (5 to
8 amino acid substitutions per gene). Most of the amino acid
substitutions were present in the framework regions, with only
one consensus mutation, S167N, being observed in the CDR1
light chain of all four clones (data not shown). S167 is located at
the interface of the cocrystal of the 80R-RBD complex (12), indi-
FIG 1 Comparison of fluorescence histograms. E. coli spheroplasts were labeled with 20 nM RBD, and binding was detected with 200 nM anti-FLAG PE. (A)
Mean fluorescence intensity (M) of E. coli spheroplast clones recovered after three successive rounds of sorting compared to a library of randommutants of the
80R scFv. (B) Mean fluorescence intensity (M) of E. coli cells expressing the RS2 and SK4 scFvs compared to 80R scFv.
TABLE 1 Equilibrium dissociation constant values (KDs) of scAbs with
RBD, as measured by SPR analysis
Clonea ka (1/Ms) kd (1/s) KD (nM)
Fold
difference
80R 1.50 106 0.06 1.60 103 0.001 10.5 0.09 1
RS2 2.69 106 0.12 1.34 104 0.43 0.05 0.01 210
SK4 2.03 106 0.8 6.91 105 0.9 0.037 0.01 270
RSK 1.73 105 0.009 1.91 104 0.4 0.11 0.03 95
a 80R, parental clone; RS2, isolated from round 1 screening; SK4, isolated from round 2
screening; RSK, 80R with S167N, N57S, and S188N mutations.
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cating its possible involvement in RBD binding. The significance
of this mutation was recently highlighted by the studies of Sui and
coworkers (26), who reported that an S167N substitution in 80R is
important for broad neutralization of SARS-CoV icUrbani strain
escape variants containing a D480A or D480G mutation.
The four high-affinity clones described above, together with
the parental antibody 80R, were subjected to in vitro recombina-
tion by DNA shuffling followed by random mutagenesis using
error-prone PCR. In DNA shuffling reactions, the 80R scFv was
used at a 4-fold molar excess in order to reduce the number of
neutral mutations. Two libraries were constructed, a shuffled li-
brary comprising 5.4  107 transformants and an error-prone
library of 1.5 107 transformants. The libraries were pooled and
screened by APEx with antigen concentrations starting at 20 nM
in the first round and decreasing to 5 nM in the third and final
round. The antigen dissociation rate constants for 80 clones from
the third round were analyzed by SPR analysis, and two clones
with lower off rates were identified. SPR analysis of the purified
monomeric scAb protein from the highest-affinity clone, SK4,
yielded a KD value of 37 pM and a koff of 6.91 10
5 s1 (Fig. 1B;
Table 1). Overall, the SK4 antibody fragment displayed 270-fold
higher affinity than 80R and contained eight amino acid substitu-
tions, including three mutations in common with RS2: N57S,
S167N, and S188N (Fig. 2).
To determine the role of the N57S, S167N, and S188N amino
acid substitutions in affinity enhancement, the respective muta-
tions were introduced into the 80R scAb by site-directed mu-
tagenesis to construct a variant referred to as RSK (Fig. 2). SPR
analysis of the RSK antibody fragment revealed a KD value of 110
pM, indicating that some or all of these three amino acid substi-
tutions confer affinity improvement (Fig. 2; Table 1).
SARSCoVneutralization and escape.To evaluate the neutral-
izing ability of the purified 80R, SK4, and RSK scAbs, we con-
ducted plaque reduction neutralization titer assays with each of
the scAbs against SARS-CoV (icUrbani). As expected, the neutral-
ization potencies of the antibodies increased according to affinity.
Compared to 80R (IC50, 0.722 g/ml), both RSK and SK4 exhib-
ited 10-fold-greater neutralization (IC50, 0.069 g/ml and 0.059
g/ml, respectively) (Fig. 3). For antibodies 80R and RSK, in vitro
FIG 2 Sequence comparison of the engineered, high-affinity variants RS2, SK4, and RSK with parental 80R scFv. Single-chain antibody fragments were
constructed in the variable heavy (VH)–linker–variable light (VL) orientation.
FIG3 Neutralization activity of the SK4 andRSK scAbs in comparison to 80R.
Neutralization activity was tested by plaque reduction assay against icUrbani.
Approximately 100 PFU of icUrbani was incubated with the scAb dilution
series. The percentage neutralization was calculated as [100  (number of
plaques with antibody/number of plaques without antibody)] 100.
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neutralization escape mutants of the icUrbani strain emerged
after three passages in cell culture, and four plaques for each
antibody were picked for sequence analysis. Three of the four
80R escape mutants carried a mutation from aspartic acid to
alanine at position 480 (D480A), and one had a mutation of
aspartic acid to tyrosine (D480Y), replicating the D480 residue
identified by previous selection with the full IgG version of this
antibody (26, 28). In the case of the RSK antibody, three of the
four escape variants had the D480Y mutation and one had a
Y436H mutation (Table 2).
Importantly, the SK4 antibody exhibited very highneutralizing
potency, and 20gwas sufficient to completely extinguish 1 106
PFU of the parent virus, yielding no escape variants. Therefore,
the initial concentration of SK4 scAb was decreased to reduce the
selective pressure and was incrementally increased over multiple
viral passages. A total of nine plaques were isolated from the final
selection with 20 g SK4 and sequenced.
All nine of the isolated escape mutants contained two muta-
tions: N479I and D480Y (Table 2). Both D480 and N479 have
been found to be highly adapted RBD residues that allow specific
binding to hACE2, andmutations at these positions decrease their
affinity for hACE2 and hence infectivity (37). D480 has been
shown to have a critical role in the binding of the parental anti-
body 80R to the RBD (12, 28), and substitution to a tyrosine has
been shown not to affect the binding of the RBD (and therefore
the virus) to the human ACE2 receptor (34). Themutation N479I
had been found in bananin-resistant virus, and this position is
found to correspond to a highly variable site in the RBD (33).
Cross neutralization studies with mutant viruses encoding ei-
ther D480A or D480Y, which mediated escape from 80R and its
derivatives, were performed with all three antibodies (Fig. 4). Im-
portantly, SK4 successfully neutralized both escape mutants, sug-
gesting an enhanced role for high affinity in overcoming the effect
of D480 substitutions. We note, however, that none of the scAbs
could neutralize the civet strain icHC/SZ/61/03 or the mouse-
adapted variant of the human 03/04 strain, icGD03MA; the latter
strain carries a Y436Hmutation associatedwith increasedmACE2
receptor usage (1, 19) (data not shown). The spike proteins of
GD03 MA and HC/SZ/61/03 each differ from that of the
icUrbani strain at six other amino acid positions within the
RBD (Table 3), and evidently, at least some of these are critical
for antibody binding.
To further assess the breadth of SK4 neutralization, we tested
SK4 neutralization against several viruses that emerged as escape
variants to other monoclonal antibodies reported earlier (21, 26).
These viruses contained single substitutions in the RBD, both
within and outside the 80R/SK4 interface. Two escape variants,
L443R and T332I, were developed under selection with the
broadly neutralizing antibodies s230.15 and s109.8, respectively
(21). Residue 443 is a contact interface site withACE2 but notwith
80R, while residue 332 does not directly interface with either 80R
or ACE2. The escape variants Y436H, Y442S, N479I (data not
shown), and D480G emerged following selection with 80R deriv-
ative antibodies and contain substitutions that interface with 80R
and, except forD480G, also interfacewith theACE2 receptor (12).
SK4 was capable of neutralizing all six of these antibody escape
variants. Three of the escape variants, namely, Y436H, Y442S, and
T332I, were neutralized with an efficacy comparable to that ob-
served with icUrbani (IC50s of 0.049 g/ml, 0.039 g/ml, and
0.109 g/ml, respectively, compared to 0.059 g/ml for icSARS)
(Fig. 5). Importantly, SK4 neutralized three other escape variants,
with IC50s lower than the IC50 displayed by 80R for icUrbani
[0.234 g/ml (L443R), 0.432 g/ml (N479I), and 0.542 g/ml
(D480G), compared to an IC50 of 0.722 g/ml for 80R with
icUrbani]. Thus, viruses containing amino acid substitutions at
either N479 or D480, which when combined mediated escape
from SK4, were neutralized with a lower IC50 than that of 80R for
icUrbani.
DISCUSSION
SARS was the first new major infectious disease to challenge the
world population in the 21st century (42). Though the number of
deaths resulting from the disease was small in comparison to pre-
vious pandemics, such as those caused by plague and influenza,
the widespread fear and resulting travel restrictions resulted in a
global economic cost estimated at 59 billion dollars (42). Since the
identification of the virus, significant research effort has been fo-
cused on the development of neutralizing antibodies for use in
both prophylaxis and therapy. Antibodies targeting the RBD re-
gion of the viral spike S protein have been shown to be protective
FIG 4 Cross neutralization studies of high-affinity scAbs with escape mutants
with the D480A and D480Y mutations.
TABLE 3 Amino acid differences in the RBD of the spike protein
Strain
Amino acid at position:
344 360 436 472 479 480 487
Urbani (human 02/03) K F Y L N D T
HC/SZ/61/03 (civet) R S Y P R G S
GD03MA (mouse-adapted
human 03/04)
R S H P N G S
TABLE 2 Amino acid changes in the RBD of spike protein found in the
neutralization escape mutants
ScAb Mutation(s)
No. of clones with mutation/
total sequenced
80R D480A 3/4
D480Y 1/4
SK4 N479I D480Y 9/9
RSK D480Y 3/4
Y436H 1/4
Rani et al.
9118 jvi.asm.org Journal of Virology
in both in vitro and in the mouse challenge model by blocking the
viral attachment to the host cell receptor (27, 28, 44). However,
the SARS-CoV S protein is subject to antigenic drift that has been
documented both in clinical isolates and in escape variants iden-
tified from in vitro antibody neutralization experiments. The use
of antibody cocktails consisting of multiple monoclonal antibod-
ies for preventing the evolution of escape mutants is generally
impractical as a therapeutic approach, due to both high cost and
long development times. Alternatively, we show here that anti-
body engineering strategies can be employed to induce broader
neutralization breadth and/or higher potency based on affinity
improvement. Earlier, Sui and coworkers developed broadly neu-
tralizing antibodies by selecting for variants of 80R that could
recognize the RBD D480A or D480G escape mutants as well as
icUrbani (26) by relying on a priori knowledge of naturally occur-
ring escape mutations in the RBD.
Here we used random mutagenesis and screening using the
bacterial display technique APEx (9) to engineer a series of 80R
scFv variants with increased antigen affinity. Variants with disso-
ciation constants (KDs) of 0.86 nM, 50 pM, and 37 pM were ob-
tained, representing a 	270-fold improvement compared to the
parent 80R antibody (KD of 10.5 nM on a BIAcore 3000 instru-
ment) (Table 1). Only one consensus mutation, S167N, in CDR1
of the light chain, was observed in all of the affinity-improved
variants (Fig. 2). Interestingly, S167N was also identified by Sui
and coworkers in all 80R variants selected to bind to RBD(D480A)
or RBD(D480G) and showing broader neutralization (26). How-
ever, the S167N-containing variants in that study displayed only a
modest (3-fold) increase in antigen affinity. A structure-based
prediction of the interaction between these antibody variants with
RBD suggests that in wild-type 80R, S167 is proximal to D480 of
the RBD and likely interacts with D480, perhaps through a hydro-
gen-bondedwatermolecule. The bulkier S167Nmutation appears
to preclude the presence of any bound water molecule for steric
reasons. The slightly bulkier Asn likely moves the hydrogen bind-
ing potential away from D480, allowing a higher-affinity electro-
static interaction between D480 and R166 (Fig. 6). Two more
mutations, N57S and S188N, were conserved in the high-affinity
variants RS2 and SK4 (Fig. 2). When S167N, N57S, and S188N
were introduced into 80R, the affinity of the resulting antibody,
RSK, increased nearly 100-fold, suggesting that the combination
of all threemutations allows amuchbetter fit to theRBD interface.
In addition to the enhanced binding to D480, the S167N substi-
tution may also mediate direct interactions with N479. Finally,
molecular modeling indicates that the N57S mutation removes
interactions with R426 and T485 of the RBD, suggesting that these
mutations work in concert to allow a better fit to the RBD inter-
face. (Fig. 6).
Our in vitro neutralization studies have provided compelling
evidence that an antibody engineered with higher affinity can lead
tomore potent and broader virus neutralization. In particular, the
SK4 and RSK antibody fragments exhibitedmarkedly higher neu-
tralization potency against the icUrbani strain (Fig. 3) than 80R.
In addition, cross neutralization studies revealed that SK4 success-
fully neutralized the 80R escape mutants containing either the
D480AorD480Ymutation in theRBD. Thesemutations probably
eliminate the electrostatic interaction between D480 of the RBD
and R166 of SK4. However, the polar interactions of N167, N188,
and N201 of SK4 with N473, Y442, and N479 of the RBD would
probably be sufficient to preserve strong binding between SK4 and
these mutants (Fig. 6).
Individually, the substitutions N479I and D480G each cause a
shift in neutralization that is nonetheless insufficient to escape
SK4, reinforcing the necessity of double substitutions to escape
the high-affinity neutralization by SK4. Additional substitutions
either selected by 80R-derived antibodies or derived indepen-
dently of 80R antibodies are also incapable of providing escape
from SK4. It is worth noting, however, that while SK4 is capable of
neutralizing each of the single-substitution spike variants we
tested, it is unable to neutralize the more divergent spikes, i.e.,
those containing variants in six or seven positions relative to the
icUrbani strain. This suggests that high-affinity neutralizing anti-
bodies like SK4 would provide excellent resistance to escape and
would be best paired with a broadly neutralizing antibody for a
highly effective therapeutic cocktail.
Just as important as neutralization breadth, higher affinity ap-
peared to suppress the formation of viral escape mutants. At a
concentration of 80R that readily gave rise to escape mutants,
incubation with the highest-affinity antibody, SK4, led to no CPE
or viral plaques aftermultiple attempts. In order to further under-
stand the potential role affinity might play during simulated in-
fection, the anti-RBD antibodies were intentionally used at sub-
neutralizing concentrations in an effort to generate viral escape
mutants. Sequencing revealed that the most common RBDmuta-
tion observed in the escape mutants generated by all antibodies
was D480Y. For SK4, the highest-affinity antibody in the study,
FIG 5 SK4 neutralization of escape variants. Neutralization activity of SK4 was tested against escape variants, and the IC50s were compared to that of icUrbani.
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escape mutants could be generated only when the concentration
of antibody was reduced further, and it required twomutations in
the RBD: N479I and D480Y. The accumulation of two mutations
for escape from the action of the neutralizing antibody would of
course be expected to be a much more rare event, and thus the
incidence of such escape variants in a therapeutic setting would
likely be low. However, we do note that even SK4 failed to neu-
tralize SARS-CoV HC/SZ/61/03 and GD03MA, presumably be-
cause the RBD in these strains contains multiple mutations that
drastically alter the character of the binding epitope (Table 3).
All of the high-affinity 80R variants used in this study were
isolated after just one round of random mutagenesis followed by
DNA shuffling using bacterial display by APEx. This approach
should be equally applicable to new and evolving strains and could
be employed for the generation of SK4 variants that can also rec-
ognize civet and human strains that presently are not neutralized
by this antibody.
A number of studies have established that antibody affinity
plays a critical role in toxin or virus neutralization potency in vivo
(17, 36). It is thought that during the germinal center reaction in
the immune system, kinetic considerations impose a limit on the
affinity during B-lymphocyte selection, keeping KD values in the
range of 1 nM (5). Thus, antibodies displaying higher affinities,
with KDs in the picomolar range or lower (4), typically must be
generated using in vitromutagenesis and screening techniques.
In a recent study, Zhang et al. used a sequential antigen pan-
ning (SAP) method and successfully isolated broadly cross-reac-
tive antibodies with two- to threefold lower IC50s than the parent
HIV-1-neutralizing antibody scFv X5 (41). Upon further charac-
terization, they found that the highly potentm9 antibody not only
exhibited broad neutralizing activity but also suppressed the gen-
eration of escape mutants upon immune selection (40). Addi-
tional studies on broadly neutralizing antibodies to HIV from
memory B cells also suggest that affinity has an important role in
breadth and potency of neutralization (23, 31).
However, one needs to proceed with caution. In the case of
motavizumab, a high-affinity variant of palivizumab (Synagis), a
higher incidence of immunogenicity was seen in phase III clinical
trials that led to discontinuation of its development as a therapeu-
tic agent (2, 31, 43). Collectively, our results together with evi-
dence from earlier studies support the notion that very high-af-
finity neutralizing antibodies may be particularly useful in a
therapeutic setting and suppress the emergence of escape variants.
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